Early Signs of Altitude Illness in Patients With COPD

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Self-Monitoring for Early Signs of Altitude Illness in Patients With Chronic Obstructive Pulmonary Disease. A Diagnostic Test Accuracy Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03957759
• Other study ID #: 01-8/464-14
• Status: Completed
• Start date: May 20, 2019
• Est. completion date: August 8, 2021

Study information

• Verified date: November 2022
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel.

Description:

This study evaluates whether structured self-monitoring (SSM) by a symptom checklist in combination with a pulse oximeter worn at the wrist allows lowlanders with COPD to accurately identify whether or not they will experience an altitude-related illness during altitude travel. After baseline evaluation at 760 m, patients will travel by bus within 3-5 h to the Tuja Ashu high altitude clinic at 3'100 m and stay there for 2 days. During this period, participants will perform SSM. They are instructed to report to study personnel if they fulfill predefined criteria for impeding altitude-related illness. A planned interim analysis will be performed after the first year of the study or after completion of study by 80 participants, whichever comes first to allow any necessary adaptations of the sample size or terminate the study early for futility or high accuracy of the index test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 153
• Est. completion date: August 8, 2021
• Est. primary completion date: August 8, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria

• Male and female patients, age 18-75 yrs.
• COPD diagnosed according to GOLD, FEV1 40-80% predicted, SpO2 =92%, PaCO2 <6 kPa at 760 m.
• Born, raised and currently living at low altitude (<800 m).
• Written informed consent. Exclusion criteria
• COPD exacerbation, very severe COPD with hypoxemia at low altitude (FEV1 <40% predicted; oxygen saturation on room air <92% or hypercapnia at 760 m).
• Other lung disease or disorder of control of breathing
• Comorbidities such as uncontrolled cardiovascular disease, i.e., unstable systemic arterial hypertension, coronary artery disease; previous stroke, internal, neurologic, rheumatologic or psychiatric disease that interfere with protocol compliance including current heavy smoking (>20 cigarettes per day)

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Diagnostic Test:
• Structured self-monitoring during an altitude ascent and stay at high altitude
Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).

Locations

Country	Name	City	State
Kyrgyzstan	National Center of Cardiology and Internal Medicine	Bishkek

Sponsors (2)

Lead Sponsor	Collaborator
University of Zurich	National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

Country where clinical trial is conducted

Kyrgyzstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic accurarcy measures of structured self-monitoring	Diagnostic performance includes sensitivity, specificity, positive and negative predictive values, and receiver operator curve area under the the curve. The diagnostic performance will be compared statistically using c-statistics against the reference test. Reference test will be the occurence of altitude-related illness defined as the following: AMS defined by the Lake Louise questionnaire score or with AMSc score; severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min; intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.; dyspnea or discomfort at rest requiring treatment with oxygen; chest pain or ECG signs of cardiac ischemia; severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg; new onset neurologic impairment; Any condition that requires study withdrawal according to the decision of the independent physician	Day 1 to 3 at 3100m
Secondary	Acute mountain sickness severity assessed by the Lake Louise score	The severity of acute mountain sickness will be assessed by the Lake Louise questionnaire. The severity will be calculated when the presence of headache and at least one of the following symptoms is present: gastrointestinal upset, fatigue or weakness and dizziness or lightheadedness. Each of the four questions is asked with the corresponding 0 to 3 rating of the response (0 = Not present, 1 = mild, 2 = moderate, 3 = severe). The sum of the responses on these questions is then calculated, resulting in the AMS severity.	Day 1 to 3 at 3100m
Secondary	Altitude-related illness, incidence	Incidence of ARI during the stay at 3100 m.; ARI is defined as the following: AMS defined by the Lake Louise questionnaire score or with AMSc score; severe hypoxemia (SpO2 <80% at rest >30 min; or SpO2 <75% at rest >15 min; intercurrent illness that cannot be relieved by simple measures such as paracetamol 3x500 mg/day, inhalation of bronchodilators.; dyspnea or discomfort at rest requiring treatment with oxygen; chest pain or ECG signs of cardiac ischemia; severe hypertension: systolic blood pressure >200 mmHg, diastolic blood pressure >110 mmHg; new onset neurologic impairment; Any condition that requires study withdrawal according to the decision of the independent physician	Day 1 to 3 at 3100m
Secondary	Spirometric measurement of forced expiratory volume in one second	Altitude-induced change in the forced expiratory volume in one between 760 and 3100m	Day 2 at 760 and 3100m
Secondary	Arterial partial pressure of oxygen	Altitude-induced change in arterial partial pressure of oxygen assessed by arterial blood gas puncture at 760 and 3100m	Day 2 at 760 and 3100m
Secondary	Six-minute walk distance in meters	Altitude-induced change in the six-minute walk distance assessed by the six-minute walk test performed at 760 and 3100m	Day 2 at 760 and 3100m
Secondary	Changes in ST-Segment of the ECG during ergometry	Altitude-induced change in the ST-Segment of the ECG assessed during a maximal ergometry test performed at 760 and 3100m	Day 1 at 760 and 3100m